Remdesivir has ‘little effect’ on Covid-19 death risks, WHO study says | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Friday
September 22, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
FRIDAY, SEPTEMBER 22, 2023
Remdesivir has ‘little effect’ on Covid-19 death risks, WHO study says

Coronavirus chronicle

Reuters
16 October, 2020, 08:50 am
Last modified: 16 October, 2020, 09:53 am

Related News

  • WHO praises Bangladesh govt efforts for overall health development
  • Saima Wazed nominated for WHO regional director
  • WHO holds first traditional medicine summit
  • Bangladesh reports 32 more Covid-19 cases
  • Point of no return: Australians fight for the right to work from home permanently

Remdesivir has ‘little effect’ on Covid-19 death risks, WHO study says

The study found the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with Covid-19

Reuters
16 October, 2020, 08:50 am
Last modified: 16 October, 2020, 09:53 am
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (Covid-19), during the outbreak of the coronavirus disease (Covid-19), in Oceanside, California, US, April 29, 2020. Photo: Reuters
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (Covid-19), during the outbreak of the coronavirus disease (Covid-19), in Oceanside, California, US, April 29, 2020. Photo: Reuters

Gilead Sciences Inc's GILD.O remdesivir had little or no effect on Covid-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.

The antiviral medication, among the first to be used as a treatment for Covid-19, was one of the drugs recently used to treat US President Donald Trump's coronavirus infection.

The results are from WHO's "Solidarity" trial, which evaluated the effects of four potential drug regimens, including remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, in 11,266 adult patients across more than 30 countries.

The study found the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with Covid-19, the WHO said on Thursday.

The results of the trial are yet to be reviewed and were uploaded on the preprint server medRxiv. 

Earlier this month, data from a US study of remdesivir by Gilead showed the treatment cut Covid-19 recovery time by five days compared with patients who got a placebo in a trial comprising 1,062 patients.

"The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of remdesivir," Gilead told Reuters.

"We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design."

WHO chief scientist Soumya Swaminathan said on Wednesday that during the study, hydroxychloroquine and lopinavir/ritonavir were stopped in June after they proved ineffective, but other trials continued in more than 500 hospitals and 30 countries.

"We're looking at what's next. We're looking at monoclonal anti-bodies, we're looking at immunomodulators and some of the newer anti-viral drugs that have been developed in the last few months," Swaminathan said.

Remdesivir received emergency use authorization from the US Food and Drug Administration on May 1, and has since been authorized for use in several countries.

Top News / World+Biz

remdesivir / WHO / Covid -19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: @UnderSecStateJ/X
    PM Hasina, Uzra Zeya meet; discuss importance of free, fair elections
  • Roads in front of New Market submerged on 22 September 2023. Photo: TBS
    A night of horror for Dhaka residents, many areas still underwater
  • Workers collect indigo leaves at a farm in Rangpur Sadar upazila. An important source of natural infigo dye in the 19th century in colonial India, the plant is seeing a revival through researchers and enthusiasts. The photo was taken recently. Photo: Khorshed Alam
    Indigo farming: Once a curse, now a blessing

Related News

  • WHO praises Bangladesh govt efforts for overall health development
  • Saima Wazed nominated for WHO regional director
  • WHO holds first traditional medicine summit
  • Bangladesh reports 32 more Covid-19 cases
  • Point of no return: Australians fight for the right to work from home permanently

Features

Why is the fixed exchange rate for dollars failing?

Why is the fixed exchange rate for dollars failing?

1d | Panorama
At present, there are about 200 freezing vans operating in Dhaka city. Photo: Nayem Ali

Rising temperature is driving up the use of freezing vans

1h | Features
Illustration: TBS

'Stop subsidising the status quo to avoid middle-income trap'

6h | Panorama
Mountain gorillas are vulnerable species, only found in the willderness. Photo: Muntasir Akash

Against all odds: My encounters with mountain gorillas in Rwanda

1d | Earth

More Videos from TBS

After almost two months, the Ukrainian grain ship left the Black Sea port

After almost two months, the Ukrainian grain ship left the Black Sea port

19h | TBS World
Revenue collection rises 15% in first two months of FY24

Revenue collection rises 15% in first two months of FY24

16h | TBS Economy
Fans call for Amir’s inclusion after Naseem Shah's injury

Fans call for Amir’s inclusion after Naseem Shah's injury

17h | TBS SPORTS
The need for a circular economy in Bangladesh

The need for a circular economy in Bangladesh

20h | TBS Face to Face
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]